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Abstract
Objective: Healthy lifestyle habits are the cornerstone in the management of
familial hypercholesterolaemia (FH). Nevertheless, dietary studies on FH-affected
populations are scarce. The present study analyses dietary habits, adherence to a
Mediterranean diet pattern and physical activity in an adult population with FH
and compares them with their non-affected relatives.
Design: Cross-sectional study.
Setting: Data came from SAFEHEART, a nationwide study in Spain.
Participants: Individuals (n 3714) aged ≥18 years with a genetic diagnosis of FH
(n 2736) and their non-affected relatives (n 978). Food consumption was
evaluated using a validated FFQ.
Results: Total energy intake was lower in FH patients v. non-affected relatives
(P< 0·005). Percentage of energy from fats was also lower in the FH population
(35% in men, 36% in women) v. those non-affected (38% in both sexes,
P< 0·005), due to the lower consumption of saturated fats (12·1% in FH patients,
13·2% in non-affected, P< 0·005). Consumption of sugars was lower in FH
patients v. non-affected relatives (P< 0·05). Consumption of vegetables, fish and
skimmed milk was higher in the FH population (P< 0·005). Patients with FH
showed greater adherence to a Mediterranean diet pattern v. non-affected relatives
(P< 0·005). Active smoking was lower and moderate physical activity was higher
in people with FH, especially women (P< 0·005).
Conclusions: Adult patients with FH report healthier lifestyles than their non-
affected family members. They eat a healthier diet, perform more physical activity
and smoke less. However, this patient group’s consumption of saturated fats and
sugars still exceeds guidelines.
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Familial hypercholesterolaemia (FH) is a genetic disorder
characterized by high LDL-cholesterol level and a higher
risk of premature atherosclerotic CVD(1). FH is caused by
mutations in the LDL receptor gene (LDLR) and, less fre-
quently, in the apolipoprotein B gene (APOB). Although
FH highly increases cardiovascular risk, atherosclerotic
CVD prevalence varies substantially by cohort and coun-
try, even across cases with the same genetic mutation(2–4).
These findings suggest that environmental, metabolic and
genetic factors could explain the differences in the CVD
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burden of these patients(5). In fact, a recent study of the
SAFEHEART study (Spanish Familial Hypercholester-
olemia Cohort Study) identified BMI increase, tobacco
consumption and hypertension as predictive risk factors
for the development of CVD in FH patients(6).
At the population level, diet is one of the most important
environmental factors affecting LDL-cholesterol level as
well as other CVD risk factors(7–9). Nevertheless, dietary
studies on FH-affected populations are scarce. Studies in
children with FH in Norway showed that a dietary proto-
col focused on reducing saturated fat consumption did
impact patients’ lipid profiles favourably(10,11). Although
most patients with FH will require lipid-lowering therapy
for life(12–14), main clinical guidelines also include a series
of dietary and nutritional recommendations as part of
treatment(12,15,16).
The main objective of the present study was to describe
the lifestyle habits, especially diet-related, the degree of
adherence to a Mediterranean-type diet and the rela-
tionship with CVD among individuals aged ≥18 years
with FH and their relatives registered at the SAFEHEART
cohort(17).
Methods
Study design and participants
Data came from the SAFEHEART study, the design and
methodology of which have been previously descri-
bed(17). Briefly, SAFEHEART is a prospective, multicentre,
nationwide study of a cohort of individuals in Spain with
molecular diagnosis of FH and their non-FH affected
family members. From January 2004 to January 2016, the
study enrolled 4217 participants from 829 families. The
local ethics committee of the University Hospital Funda-
ción Jiménez Díaz (Madrid) approved the study and all
participants signed informed consents.
Exclusion criteria included: individuals under 18 years
of age (n 269); failure to complete a semi-quantitative
validated FFQ at inclusion (n 230); and reporting either an
excessively high (>14 644 kJ/d (>3500 kcal/d) for women
and >17 573 kJ/d (>4200 kcal/d) for men) or an exces-
sively low energy intake (<2092 kJ/d (<500 kcal/d) for
women and <3347 kJ/d (<800 kcal/d) for men) to elim-
inate outliers(18) (n 4). Thus, herein we analysed the data
from the remaining 3714 individuals.
Upon entering the study, participants completed a
113-item FFQ, previously validated for this popula-
tion(19). The FFQ included questions about the con-
sumption of each food during the previous year,
specifying the size of the typical portion and consump-
tion frequency (never before or number of times per
year, per month, per week or per day). Based on the FFQ
data, adherence to the Mediterranean diet (MD) was
evaluated with the MEDAS(20) questionnaire, an instru-
ment validated and developed to assess the degree of
adherence to a traditional MD pattern in the general
population(21).
Study variables
A clinical history and ad hoc questionnaires collected
participant demographic and clinical characteristics
including age, history of CVD, common CVD risk factors
(type 2 diabetes, hypertension, smoking) and level of
physical activity. A physical examination included stan-
dardized measurement of weight (kg) and height (cm),
BMI (kg/m2) and waist circumference (cm). Blood pres-
sure was measured twice in the supine position using an
Omron MX3 sphygmomanometer.
Energy and nutrient intakes were estimated using the
Spanish official food composition tables(22). Two indices
were used to assess fat quality: (i) the energy contribution
of the different types of fatty acids according to their
degree of saturation, i.e. SFA, MUFA and PUFA; and (ii) the
relationship among them, i.e. PUFA:SFA and (PUFA+
MUFA):SFA.
Adherence to the MD was evaluated with the fourteen-
item MEDAS(20), comprising two items on eating habits,
eight items on the consumption frequency of traditional
MD foods and four items to assess low consumption
levels of non-recommended foods. Each item is scored 0
or 1 for a total score ranging from 0 to 14. A higher score
indicates greater adherence to a MD. We defined(23) high
adherence as a score ≥ 9 and moderate adherence as a
score ≥7. The MEDAS score was calculated from the FFQ
data. However, since the FFQ does not specify the
amount of olive oil used just for sofrito (a sauce consisting
of tomato, onion and garlic, slow-cooked with olive oil),
we cannot know whether participants met or did not
meet the fourteenth MEDAS objective of sofrito con-
sumption ≥2/week. Therefore this item was excluded,
and the total score was based on a maximum of 13 points.
Physical activity was measured with the reduced version
of the International Physical Activity Questionnaire
(IPAQ)(24).
Statistical analysis
We performed descriptive analyses with the objective of
describing the dietary habits of the SAFEHEART cohort and
comparing the regular diet of participants with and without
FH. Variables were analysed separately by sex. Qualitative
variables are described by number of cases and corre-
sponding percentages; normally distributed quantitative
variables are described by their means and SD; and non-
normally distributed quantitative variables are described
with the median and interquartile range. The χ2 test,
Student’s t test for independent data and theMann–Whitney
U test for independent data were used to compare differ-
ences across qualitative, normally distributed quantitative
and non-normally distributed quantitative data, respec-
tively. Statistical significance was set at two-sided P< 0·05.
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Results
Description of the sample
Participant characteristics are shown in Table 1. Of the
3714 individuals, 2736 (73·6%) had molecular confirma-
tion of FH and 978 were non-affected family members
(negative genetic study; control group). Over half (54%)
were women and the mean age was 45·1 (SD 15·6) years.
The majority of patients were on lipid-lowering treatment
at study entry. Mean BMI was 26·9 (SD 4·1) kg/m2 in men
and 25·8 (SD 5·3) kg/m2 in women (P< 0·005). Over one-
third of the entire sample (36·7%) was overweight and
20·2% were obese. We did not find differences in BMI and
prevalence of overweight or obesity between participants
with and without FH. Prevalence of hypertension and type
2 diabetes was 14·7 and 4·0%, respectively, without dif-
ferences by FH status. More men than women were
current smokers (32·1 and 24·8%, respectively; P< 0·005)
and more controls than FH patients smoked (33·8 and
26·3%, respectively; P< 0·005). Patients with FH and a
history of CVD reported the lowest rate of tobacco con-
sumption (12·9%).
A history of CVD was reported by 19·4% of men with
FH and 7·9% without FH (P< 0·005). Similarly, 8·1 and
2·1% of women with and without FH had a history of
CVD, respectively (P< 0·005).
Physical activity
More women (62·3%) reported moderate physical activity
compared with men (51·6%; P< 0·005); further, women
with FH were more likely to report moderate physical
activity than those in the control group (P< 0·005). Within
the FH group, a higher proportion of patients who had
already suffered CVD reported performing moderate
physical activity than those with no CVD history (64·4 v.
58·4%, respectively; P< 0·05; data not shown).
Consumption of energy and nutrients
Table 2 shows the average consumption of macro- and
micronutrients by sex and FH diagnosis. The mean daily
energy intake was 8401 (SD 1966) kJ (2008 (SD 470) kcal),
being higher in men and in non-FH individuals
(P< 0·005). Carbohydrates accounted for 43·0% of energy,
fats for 37·0% and proteins for 18·1%.
In both sexes, the percentage of energy derived from
complex carbohydrates and proteins was higher in
patients with FH than the control group (P< 0·005),
whereas the percentage of energy derived from fats was
higher in the control group (P< 0·005). Table 3 shows the
average consumption of macronutrients and fatty acids by
CVD history and FH diagnosis. In both the FH group and
the non-FH affected group, the percentage of energy from
fats was higher in individuals without a history of CVD
(P< 0·005); the consumption of SFA followed a similar
pattern (P< 0·005).
Regarding the quality of the fat consumed (Fig. 1),
MUFA represented 20·7%, SFA 12·4% and PUFA 8·2% of
energy from fats. The intake of SFA was higher in the
control group for both sexes (P< 0·005), but no significant
differences were detected in the energy derived from
MUFA and PUFA between FH patients and controls. The
percentage of energy from trans-fatty acids was low (0·3–
0·4%). The relationship between unsaturated and satu-
rated fatty acids (PUFA:SFA and (PUFA+MUFA):SFA) was
significantly higher in women (P< 0·005) as well as in FH
patients (P< 0·005). The consumption of cholesterol was
higher in non-FH affected participants (P< 0·005). None of
the groups reported a mean cholesterol intake exceeding
300mg/d (nutritional objectives for the Spanish popula-
tion(25)). The cohort’s overall consumption of n-3 fatty
acids was 1·62 g/d with no substantial differences across
groups.
The mean consumption of total fibre was 31·1 (SD 8·3)
g/d. When expressing this as an intake per 4184 kJ
(1000 kcal), we detected a higher consumption in FH
patients across sexes (P< 0·005). The consumption of
sugars was lower in FH patients compared with their non-
affected relatives (P< 0·05).
Food consumption
Table 4 shows the average food consumption by sex and
FH diagnosis. Cereal consumption was significantly higher
in men than women. However, there were no differences
between FH patients and controls. Regarding the total
consumption of milk products, there were no differences
between participants with and without FH. However,
more FH patients reported consuming skimmed milk
products than non-FH participants (P< 0·005).
Regarding the sources of animal protein, a higher con-
sumption of red meats, sausages and processed meats was
observed in the controls of both sexes than their FH-
affected counterparts (P< 0·005). The average total fish
consumption was high (57 g/d) including that of blue fish;
patients with FH reported a higher total fish intake than
controls (67·1 and 60·4 g/d, respectively; P< 0·005).
Regarding vegetables, participants reported an average
consumption of 250 g/d, with patients’ intake being
higher. In terms of fruit intake, the average amount
reported was 272 g/d which is equivalent to about two
medium pieces of fruit.
In terms of beverages, we detected a significantly higher
consumption of sugary soft drinks in non-FH affected
individuals regardless of sex than among FH patients
(117·1 and 91·9 g/d, respectively; P< 0·005). In the case of
alcoholic beverages, both fermented and distilled, con-
sumption was higher in men than in women (P< 0·005).
Adherence to the Mediterranean diet
Based on the MEDAS(20) questionnaire, we observed that
over 90% of the individuals met the MD recommendation
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Table 1 Baseline characteristics of adults in the SAFEHEART study (Spanish Familial Hypercholesterolemia Cohort Study) by sex and diagnosis of familial hypercholesterolaemia (FH)
Men
(n 1708; 46%)
Women
(n 2006; 54%)
FH ( + ) FH (− ) FH ( + ) FH (− )
n, mean or
median
%, SD or
IQR
n, mean or
median
%, SD or
IQR
n, mean or
median
%, SD or
IQR
n, mean or
median
%, SD or
IQR
P†
(men v.
women)
n 1253 33·7 455 12·3 1483 39·9 523 14·1 <0·005
Age (years) 44·8 15·0 41·9** 15·2 46·9 15·9 43·5** 16·1 <0·005
BMI (kg/m2) 26·6 4·4 27·0 4·1 25·5 5·3 25·9 5·3 <0·005
Waist circumference (cm) 93·1 12·2 92·0 13·4 81·9 13·8 81·1 13·9 <0·005
Systolic aortic pressure (mmHg) 129·4 17·0 129·8 17·6 125·7 21·6 123·1* 19·3 <0·005
Diastolic aortic pressure (mmHg) 76·8 10·5 77·9 11·1 75·5 10·9 76·1 11·0 <0·005
Total cholesterol (mg/dl) 245·0 66·9 202·9** 41·4 252·9 65·3 211·4** 44·2 <0·005
TAG (mg/dl) 91 69–127 92 69–130 77 60–107 84* 61–117 <0·005
HDL-cholesterol (mg/dl) 45·1 11·0 49·3** 11·0 54·1 12·7 59·1** 13·7 <0·005
LDL-cholesterol (mg/dl) 178·1 62·4 131·4** 36·8 180·7 61·0 132·9** 38·1 0·19
Serum glucose (mg/dl) 88·2 15·7 90·6* 20·2 85·2 15·1 86·3 15·7 <0·005
Overweight‡ 562 44·8 206 45·2 440 29·6 155 29·6 <0·005
Obesity§ 261 20·8 96 21·1 285 19·2 102 19·5 <0·005
High blood pressure 169 13·5 68 14·9 237 15·9 73 14·0 0·18
Type 2 diabetes mellitus 61 4·5 22 4·3 55 3·5 24 4·2 0·13
Previous atherosclerotic CVD 244 19·4 36** 7·9 121 8·1 11** 2·1 <0·005
Family history of early atherosclerotic
CVD║
416 37·1 140 33·2 555 41·7 164** 33·2 <0·05
Active tobacco smoker 373 29·7 176** 38·6 345 23·2 154* 29·5 <0·005
Former smoker 399 31·8 103** 22·6 277 18·6 86* 16·4 <0·005
Low-intensity physical activity¶ 229 18·2 101 22·2 334 22·4 156** 29·8 <0·005
Moderate-intensity physical activity¶ 659 52·5 223 49·0 963 64·7 290** 55·4 <0·005
Vigorous-intensity physical activity¶ 365 29·1 131 28·7 190 12·7 77** 14·7 <0·005
Values are mean and SD, median and interquartile range (IQR), or n and %.
Significant difference by diagnosis of FH: *P< 0·05, **P< 0·005.
†Statistical significance set at P< 0·05.
‡Defined as BMI= 25·0–29·9 kg/m2.
§Defined BMI≥ 30·0 kg/m2.
║Family history of atherosclerotic CVD before age 60 years.
¶Measured with the reduced version of the International Physical Activity Questionnaire (IPAQ)(24).
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Table 2 Baseline nutrient intake of adults in the SAFEHEART study (Spanish Familial Hypercholesterolemia Cohort Study) by sex and diagnosis of familial hypercholesterolaemia (FH)
Men
(n 1708; 46%)
Women
(n 2006; 54%)
P‡
(men v. women)
FH ( + ) FH ( – ) FH ( + ) FH (– )
Nutrient† Mean or median SD or IQR Mean or median SD or IQR Mean or median SD or IQR Mean or median SD or IQR
Energy (kJ/d) 8573·4 1994·9 9127·8** 2103·3 8127·0 1863·1 8522·4** 1928·4 <0·005
Energy (kcal/d) 2049·1 476·8 2181·6** 502·7 1942·4 445·3 2036·9** 460·9 <0·005
Carbohydrates (E%) 42·5 6·8 41·1** 6·3 43·3 6·7 42·3** 6·6 <0·005
Sugars (g/d) 104·5 34·8 106·7 34·9 102·1 31·9 105·9* 31·9 0·06
Fibre (g/d) 30·7 8·4 29·7* 7·8 31·8 8·3 31·7 8·0 <0·005
Fibre (g/4184 kJ (1000 kcal)) 15·3 3·9 13·9** 3·5 17·0 4·1 15·9** 4·0 <0·005
Protein (E%) 17·6 2·7 17·2* 2·7 18·8 2·8 18·2** 2·8 <0·005
Animal protein (g/d) 60·1 17·6 63·6** 18·1 61·3 17·7 63·7* 18·9 0·14
Vegetable protein (g/d) 29·0 8·4 29·1 8·4 27·9 8·2 28·5 8·1 <0·005
Fat (E%) 35·7 6·4 38·0** 5·8 36·1 6·3 38·0** 6·4 0·25
Cholesterol (mg/d) 224·3 76·9 262·8** 85·8 207·9 70·0 237·2** 84·9 <0·005
MUFA (E%) 20·3 3·9 20·7 3·5 20·9 4·1 21·2 3·8 <0·005
PUFA (E%) 8·0 1·4 8·0 1·4 8·3 1·4 8·2 1·7 <0·005
SFA (E%) 12·1 2·2 13·3** 2·3 12·1 2·1 13·1** 2·2 0·30
Trans-fatty acids (g/d) 0·8 0·6 1·2** 0·7 0·7 0·5 0·9** 0·7 <0·005
Trans-fatty acids (E%) 0·36 0·2 0·47** 0·2 0·30 0·2 0·39** 0·2 <0·005
MUFA:SFA (E%) 1·70 0·3 1·57** 0·2 1·70 0·3 1·64** 0·3 <0·005
PUFA:SFA (E%) 0·67 0·1 0·61** 0·1 0·70 0·1 0·64** 0·1 <0·005
(MUFA+PUFA):SFA (E%) 2·38 0·4 2·19** 0·4 2·42 0·4 2·29** 0·4 <0·005
n-3 Fatty acids (g/d) 1·64 0·1 1·62 0·6 1·60 0·6 1·58 0·5 0·20
Alcohol (E%) 3·0 0·8–5·8 2·0 0·8–5·0 0·5 0·0–2·0 0·5 0·0–2·0 <0·005
K (mg/d) 3602·1 994·2 3572·6 975·9 3713·9 966·5 3762·2 991·2 <0·005
Na§ (mg/d) 1978·9 703·0 2087·0** 710·0 1872·2 701·4 1980·5** 737·6 <0·005
E%, percentage of energy.
Values are mean and SD, or median and interquartile range (IQR).
Energy intakes exceeding Willett’s limits have been excluded(18).
Significant difference by diagnosis of FH: *P< 0·05, **P< 0·005.
†The dietary evaluation was carried out using a validated FFQ (113-item).
‡Statistical significance set at P< 0·05.
§Na from food excluding salt.
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Table 3 Baseline nutrient intake of adults in the SAFEHEART study (Spanish Familial Hypercholesterolemia Cohort Study) by previous atherosclerotic CVD (ASCVD) and diagnosis of familial
hypercholesterolaemia (FH)
Patients with FH (n 2736) Non-affected relatives (n 978)
With ASCVD
(n 365)
Without ASCVD
(n 2371)
With ASCVD
(n 47)
Without ASCVD
(n 931)
Nutrient† Mean SD Mean SD P‡ Mean SD Mean SD P‡
Energy (kJ/d) 8040·8 1876·5 8289·8 1930·1 < 0·05 8584·3 1862·7 8815·3 2041·8 0·45
Energy (kcal/d) 1921·8 448·5 1981·3 461·3 <0·05 2051·7 445·2 2106·9 488·0 0·45
Carbohydrates (E%) 43·9 6·9 42·9 6·8 <0·05 43·7 8·1 41·7 6·5 <0·05
Sugars (g/d) 103·8 36·6 103·1 32·8 0·70 104·3 38·0 106·4 33·0 0·67
Fibre (g/4184 kJ (1000 kcal)) 17·7 4·5 16·0 4·1 <0·005 17·1 4·3 14·9 3·9 <0·005
Protein (E%) 18·1 3·0 18·3 2·9 0·23 18·4 3·2 17·7 2·8 0·15
Fat (E%) 34·4 6·6 36·2 6·3 <0·005 34·7 6·8 38·2 6·0 <0·005
Cholesterol (mg/d) 196·3 68·4 218·4 74·1 <0·005 225·0 81·7 250·4 86·4 <0·05
MUFA (E%) 20·3 4·3 20·7 4·0 0·08 19·4 4·0 21·1 3·7 <0·005
PUFA (E%) 8·1 1·6 8·2 1·4 <0·05 7·7 1·6 8·2 1·6 <0·05
SFA (E%) 11·4 2·2 12·3 2·2 <0·005 12·0 3·0 13·3 2·2 <0·005
Trans-fatty acids (g/d) 0·6 0·6 0·8 0·6 <0·005 0·8 0·8 1·1 0·8 <0·05
Trans-fatty acids (E%) 0·30 0·2 0·30 0·2 <0·005 0·34 0·3 0·44 0·3 <0·05
MUFA:SFA (E%) 1·80 0·3 1·70 0·3 <0·005 1·70 0·4 1·60 0·3 0·16
PUFA:SFA (E%) 0·70 0·2 0·70 0·1 <0·005 0·67 0·2 0·63 0·1 0·07
(MUFA+PUFA):SFA (E%) 2·50 0·4 2·40 0·4 <0·005 2·34 0·5 2·24 0·4 0·08
n-3 Fatty acids (g/d) 1·70 0·7 1·60 0·6 0·32 1·80 0·8 1·60 0·6 <0·05
Values are mean and SD.
Energy intakes exceeding Willett’s limits have been excluded(18).
†The dietary evaluation was carried out using a validated FFQ (113-item).
‡Statistical significance set at P< 0·05.
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regarding the use of olive oil as the main culinary fat, as
well as for a low consumption of animal fat. In addition,
over half of the sample consumed more than 3 servings
fish/week and consumed sugary soft drinks <1 time/d.
However, fewer than 30% of the participants reported the
minimum daily recommended intake of vegetables and
fruits.
The mean MEDAS score (out of 13 points) of the entire
cohort was 6·14 points (95% CI 6·1, 6·2), with higher
means achieved by FH patients regardless of sex than
controls (P< 0·005). However, only 10·1% of the total
sample reported a high adherence to the MD pattern
(score ≥9 points) and 31·8% reported a moderate adher-
ence (score ≥7 points), with women and FH patients
scoring higher than their counterparts (Table 5).
Given the lack of consensus regarding alcoholic bev-
erages being recommended for cardiovascular prevention,
the total score was recalculated after eliminating item 8
(wine consumption of ≥7 glasses/week). The new aver-
age score (now out of 12 points) was still significantly
higher for FH patients than controls for both sexes.
Discussion
The present study shows that adults with FH have heal-
thier dietary habits and a greater adherence to the MD
compared with their non-FH relatives. They also smoke
less, especially those individuals with history of CVD, and
are more likely to be physically active. To the best of our
knowledge, the present study is the first that analyses the
nutritional characteristics, MD adherence and other life-
styles in a large population of adults with FH.
The relationships between diet, CVD and death are
topics of major public health importance, and subjects of
great controversy. In European and North American
countries, the most enduring and consistent dietary advice
is to restrict SFA, by replacing animal fats with vegetable
oils(26). It has been shown in the PREDIMED study that a
MD supplemented with extra-virgin olive oil or nuts is
associated with a reduction in the incidence of cardio-
vascular events and death in a high-risk primary preven-
tion population in Spain, explained in part by the intake of
MUFA and PUFA(7). One of the inclusion criteria in the
PREDIMED study was an LDL-cholesterol level >160mg/dl
and therefore it is possible that some few cases of FH were
included in the study; however, there are no specific results
available regarding this population.
A key index of diet quality is the energy profile that was
more balanced in patients with FH than in their non-FH
relatives. Energy intake and BMI were significantly lower
in FH patients. In addition, the prevalence of overweight
and obesity in this population was slightly lower than in
the Spanish general population (39·3% of overweight and
21·6% of obesity)(27).
Patients reported a lower energy intake from total and
saturated fat due to a lower intake of whole milk, red
meat, sausages and precooked foods. In the current study,
fats accounted for 37% of energy. The PURE study
reported that total fat intake in quintile 5 (33·3–38·3% of
energy) was associated with a lower risk of total mortality
and there was no association with CVD(9). Initial PURE
study findings challenge conventional diet–disease tenets
that are largely based on observational associations in
European and North American populations, adding to the
uncertainty about what constitutes a healthy diet(9).
Trans-fatty acids
SFA
PUFA
MUFA
0 5 10 15 20 25
0.34
0.43
12.1
13.2
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% of energy
Fig. 1 Percentage of energy from fatty acids in the SAFEHEART study (Spanish Familial Hypercholesterolemia Cohort Study) by
diagnosis of familial hypercholesterolaemia (FH): , patients aged ≥18 years with a genetic diagnosis of FH (n 2736); , non-
affected relatives (n 978)
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Table 4 Baseline food and food group intakes of adults in the SAFEHEART study (Spanish Familial Hypercholesterolemia Cohort Study) by sex and diagnosis of familial
hypercholesterolemia (FH)
Men
(n 1708; 46%)
Women
(n 2006; 54%)
FH ( + ) FH (− ) FH ( + ) FH (− )
Food or food group† (g/d) Median or mean IQR or SD Median or mean IQR or SD Median or mean IQR or SD Median or mean IQR or SD
P‡
(men v. women)
Cereals 134 102–175 133 101–172 127 94–165 131 97–164 <0·005
Pastry 10 4–24 19** 7–40 9 3–22 14** 5–27 <0·005
Sugar and honey 5 1–10 5 1·4–10 5 0·16–10 5 0·4–10 <0·005
Milk and dairy products 330 233–474 340 232–471 382 264–530 380 264–539 <0·005
Skimmed dairy 125 0–253 0** 0–125 208 35–400 102** 0–253 <0·005
Dairy products, not skimmed 71 0–218 200** 35–325 28 0–200 142** 1–325 <0·005
Cheese 16 7–30 20** 8–40 21 8–38 22 8–42 <0·005
Meat and meat products 137 100–180 156** 114–202 125 94–163 139** 106–183 <0·005
Red meat 41 22–60 52** 29–74 37 18–55 38** 21–58 <0·005
White meat 56 38–77 56 40–78 57 41–78 59 41–82 0·06
Sausages and other meat products 28 15–50 37** 21–60 24 13–43 28** 15–50 <0·005
Eggs 17 8–25 17** 17–25 17 8–24 17** 17–25 0·17
Fish and shellfish 56 37–81 50** 35–76 61 38–92 57** 37–79 <0·005
White fish 18 18–37 18 18–37 37 18–55 37* 18–55 <0·005
Oily fish 18 18–37 18** 8–37 18 18–37 18** 8–37 0·21
Oils and fats 27 18–35 27 18–36 28 21–37 29 21–38 <0·005
Olive oil 23 16–31 22 15–32 25 17–33 25 18–35 <0·005
Butter and margarine 1·12 2·6 1·49** 3·1 1·47 3·0 1·67** 3·1 <0·005
Vegetables 231 149–339 213** 130–299 285 195–385 270* 177–368 <0·005
Legumes 14 14–28 14 14–28 14 14–28 14* 14–28 0·16
Potatoes 43 21–64 43 21–68 42 21–64 42 21–64 <0·05
Fruits 250 138–402 220 123–359 296 179–457 297 167–443 <0·005
Nuts 5 1·6–14 5 1–14 3 0·5–10 3 0·8–10 <0·005
Ready-to-eat-meals 8 2–22 12** 4–32 5 0·5–16 6* 1–17 <0·05
Coffee 50 16–100 50* 7–100 50 21–100 50 14–100 0·11
Sugary drinks 57 13–163 70** 13–200 28 2–86 35** 6–142 <0·005
Beer and wine 107 31–250 107 27–250 18 0–100 18 0–78 <0·005
Distilled beverages 1·6 0–7 2* 0–7 0 0–0·8 0 0–1·6 <0·005
Values are median and interquartile range (IQR), or mean and SD.
Energy intakes exceeding Willett’s limits have been excluded(18).
Significant difference by diagnosis of FH: *P< 0·05, **P< 0·005.
†The dietary evaluation was carried out using a validated FFQ (113-item).
‡Statistical significance set at P< 0·05.
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It is well known that the quality of fat consumed affects
the plasma lipid profile(28) and other cardiovascular risk
factors; thus, it is important to know the fatty acid dis-
tribution in this specific population with high cardiovas-
cular risk. In the SAFEHEART cohort, the quality of fat
reported reaches the recommended MUFA intake (≥20%
of energy) and in parameters like (PUFA+MUFA):SFA≥ 2
and PUFA:SFA≥0·5(25). This is in part due to the high
intake of olive oil, the main source of fat in the Medi-
terranean diet, and of n-3 fatty acids. The n-3 intake in this
population was 1·62 g/d, explained by a higher con-
sumption of fish compared with the Spanish general
population(29).
Unfortunately, SFA intake was over 10% of energy in
patients with FH and in their relatives, even in those cases
with CVD. This excess consumption of SFA is similar to
that observed in the Spanish general population(29,30). On
the other hand, cholesterol consumption in both FH and
controls was below 300mg/d, meeting the dietary
recommendations(25), in contrast to findings from the
general population(30).
Regarding carbohydrate intake, the PURE study
showed that an intake over 60% of energy was asso-
ciated with an adverse impact on total and non-CVD
mortality. In the SAFEHEART cohort, carbohydrates
represented 43% of total energy, a lower consumption
compared with the 52·4% reported in the PURE study for
Europe and North America(9). Patients with FH reported a
lower consumption of carbohydrates than non-FH rela-
tives and similar to that found in the Spanish general
population(29). This is mainly explained by fewer con-
sumption of pastries and sugary soft drinks while eating
vegetables, fruits and legumes in amounts close to dietary
guidelines.
Overall, FH patients had a healthier dietary pattern than
their non-FH relatives in terms of consumption of vege-
tables, fish, skimmed milk products, red meats, sausages
and/or processed meats, butter and margarine. Patients
with FH are more aware of cardiovascular risk and,
therefore, more receptive to dietary and lifestyle advice.
This is likely to be especially true regarding fat and cho-
lesterol intake, lower energy consumption and greater
energy expenditure. Further, based on our data, women
seemed more likely to heed recommendations regarding
physical activity.
A great advantage of using a validated adherence index
to a dietary pattern is that it allows to evaluate the quality
of the overall diet more than does each individual nutrient
and/or food item. Among the many MD adherence indi-
ces, MEDAS is the only one validated in a high cardio-
vascular risk population(20). In our cohort, we found a
greater adherence to the MD pattern in patients with FH
compared with their non-FH relatives. The level of
adherence was moderate (6·14 points) and similar to that
described for the general population(31), with the differ-
ence that the score used in the current analysis was basedTa
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in thirteen items v. the usual fourteen items used in other
studies, making our score slightly better.
There are no other studies like the present one in other
FH populations; therefore, we are very limited in terms of
placing our work in the context of the existing literature.
However, our results confirm previous data observed in a
small group of children with FH reporting a healthier diet
compared with non-FH children(32). Regarding our control
group (non-FH relatives), our results show that they also
follow a healthier diet than the Spanish general popula-
tion(29,30). One may speculate that having a relative with a
genetic disorder that severely increases cardiovascular risk
has a positive impact on one’s own dietary choices.
Additionally, having a family history of CVD may increase
awareness of cardiovascular risk in the family and diet-
related risk factors for CVD. Although our population has a
higher cardiovascular risk and most of them are under
lipid-lowering therapy, the addition of a MD may improve
or attenuate other classical CVD risk factors and bio-
markers that increase cardiovascular risk(7–9,28,33).
Our results should be interpreted within the context of
the study’s limitations. First, based on the cross-sectional
nature of the study, we are unable to draw any conclu-
sions regarding whether following a better diet would
have a positive impact on the CVD burden of FH patients.
Second, even validated questionnaires rely on self-
reported data, which may be subject to recall error and
social desirability bias. The present study also has several
strengths. First, it is the largest population-based study of
individuals with a molecular diagnosis of FH assessing
nutritional intake with a comprehensive and validated
dietary questionnaire. Second, individuals included in the
SAFEHEART study are representative of FH patients
residing in a Southern European Mediterranean country,
a population that is severely understudied. Since the
sample comes from the entire Spanish territory, the
sample design reduces the selection bias. Third, indivi-
duals of the control group were part of the same families
of patients with FH, so it can be argued that detecting
significant differences would be harder given the proxi-
mity and raised awareness of CVD risk factors among
these relatives. Thus, our comparison results could be
considered conservative and we would expect larger
differences if our FH population were to be compared
with the general Spanish population.
Conclusions
Adult patients with FH report better lifestyles, mainly a
healthier diet in general and a greater adherence to the
MD in particular, than their non-FH relatives. As one
would hope, patients with FH and a history of CVD report
a lower consumption of total fat and SFA, follow dietary
recommendations best, and are the least likely to smoke.
Specifically, FH patients stand out for their high con-
sumption of vegetables, olive oil, fish and skimmed milk
products, and their low consumption of pastries, sugary
sodas and red meats. This dietary pattern translates into a
lower consumption of saturated fats and cholesterol. Yet,
this patient group’s consumption of saturated fats and
sugars still exceeds general recommendations, which
shows room for improvement and an opportunity for
targeted intervention in future longitudinal studies in our
cohort. Despite the high cardiovascular risk associated
with FH and the availability of lipid-lowering therapy,
a healthy diet and a better distribution of fat intake
could be important allies in controlling CVD-related risk
factors.
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